Amnion Life's mission
Amnion Life LLC, a medical device company, was founded to develop the AmnioBed™, an amniotic neonatal incubator system that incorporates unparalleled disruptive technology to promote ongoing development immediately following birth. Our mission is to design, patent and market safe and effective medical devices to care for preterm birth (PTB) infants.
The AmnioBed™ is designed to directly assist with the ongoing and critical development of premature babies. There are many underdeveloped areas of the body in a premature baby where AmnionBed can benefit: lungs, heart, brain, muscle, skin, immune system and more.
With premature birth, the infant is susceptible to potentially life-threatening and life-long complications. Many describe the delivery room as a “hostile environment” because it is such a shock and dramatic difference from the womb habitat. The skin is immediately compromised by exposure to air versus the amniotic fluid present in the mother’s womb. Also, the preterm birth infants at <27 weeks GA have little to no subcutaneous fat for insulation. With skin this underdeveloped and thin, the preterm infant is susceptible to hypothermia, skin breakdown, dehydration, weight loss, pressure sores, alkaline burns, and infection that can lead to sepsis and death.
Despite ongoing technology advancements, it has been acknowledged that current standard of care incubators still have many deficiencies and flaws that fall short in addressing complications, such as hypothermia and dehydration. The Amnion Life team believes that they have a viable solution to this global problem that affects over 15 Million children worldwide each year.
What Is Amnion Life?
Amnion Life LLC - has been founded to develop the AmnioBed™, an amniotic neonatal incubator system that incorporates unparalleled disruptive technology to promote ongoing development immediately following birth. This novel technology recreates a closer to natural in-womb habitat to nurture critical ongoing development to in-turn decrease short and long-term complications, common in premature births. Dr. Amir Fassihi, the company founder, developed the AmnioBed technology.
The ultimate goal of the AmnioBed™ is to directly address the target PTB infant population to improve outcomes, reduce complications and decrease costs associated with length of stay(LOS) in NICU and longer-term societal costs.